Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically and/or cytologically confirmed breast cancer~* Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen~* To have at least one measurable region~* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1~* To have adequate organ function (bone marrow, liver and renal function)~Exclusion Criteria:~* To have interstitial pneumonia or pulmonary fibrosis~* To have inflammatory breast cancer~* Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery~* To have brain metastases with symptoms~* To have severe complication (cardiac infarction, infection, drug hypersensitivity or diabetes)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).